News
Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.
The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback